Marc Goodman

“The comment around the five-year data being a review issue, did that refer to if the study just misses, then the FDA would consider the longer-term five-year data a review issue?”

“I heard your comment on inventory with Skyclaris, but could you give us a little more detail just on what you meant by growth? How much growth are we seeing in patients in the U.S.?”

“Nick, can you talk about where you think Avelity Gross to Nets will settle out in, let's say, two years after both of these indications are, you know, kind of going?”

“Is it safe to use that product at the same time as a filler and at the same time as Juveau? I'm just wondering if you need studies to kind of show that it's safe, or is it just going to be well understood by the doctors?”

“Yes, now that it looks like debut Europe is going to happen, can you help quantify that opportunity for us? And you mentioned Germany in the fourth quarter. What other countries are you expecting to launch?”